期刊文献+

HER-2阴性乳腺癌中VEGF、COX-2的表达及相关性研究 被引量:4

Expression and correlation of VEGF and COX- 2 in HER- 2 negative breast cancer
下载PDF
导出
摘要 目的:研究血管内皮生长因子(VEGF)、环氧化酶-2(COX-2)在91例HER-2阴性乳腺癌组织中的表达及相互关系,分析其与临床病理特征及预后的关系。方法:采用免疫组化SABC法,检测91例HER-2阴性乳腺癌组织中VEGF、COX-2蛋白的表达,并与临床病理特征进行相关性分析。结果:HER-2阴性乳腺癌组织中VEGF阳性表达率为94.5%,其中47.2%为高表达(+++),VEGF的表达与肿瘤大小、淋巴结转移相关(P<0.05)。HER-2阴性乳腺癌组织中COX-2阳性表达率为86.8%,其中34.0%为高表达(+++),COX-2的表达与患者年龄、组织学分级、肿瘤大小、淋巴结转移及TNM分期无关(P>0.05)。VEGF与COX-2的表达呈正相关(r=0.1798,P=0.018),VEGF/COX-2均高表达的患者淋巴结转移率高。结论:VEGF、COX-2在HER-2阴性乳腺癌组织中均高表达且两者呈正相关,联合检测VEGF、COX-2的表达对HER-2阴性乳腺癌预后判断可能具有重要价值。 Objective:To study the expression of vascular endothelial growth factor( VEGF)and cyclooxygenase-2(COX-2)in HER-2 negative breast cancer tissues of 91 patients and analyze the correlation with clinicopatho-logic features and prognosis. Methods:The expression of VEGF and COX-2 proteins in HER-2 negative breast cancer tissues of 91 patients were detected using immunohistochemistry SABC method. The relationship between COX-2 and VEGF expression was analyzed,together with clinicopathologic features. Results:The positive expression rate of VEGF was 94. 5% in the 91 HER-2 negative breast cancer tissues. The overexpression(score 3+)rate of VEGF was 47. 2%. The overexpression of VEGF was related with tumor size and lymphatic metastasis(P〈0. 05). The posi-tive expression rate of COX-2 was 86. 8% in the 91 HER-2 negative breast cancer tissues. The overexpression (score 3+)rate of COX-2 was 34. 0%. The expression of COX-2 was no correlation with age,histopathological grade,tumor size,lymphatic metastasis and TNM stage(P〉0. 05). The expression of VEGF was related to the ex-pression of COX-2(r=0. 1798,P=0. 018). Overexpression VEGF/overexpression COX-2 tumors were proved to have high lymphatic metastasis. Conclusion:In HER-2 negative breast cancer tissues,VEGF and COX-2 were both highly expressed and they showed directly correlation. The expression of VEGF and COX-2 might have great signifi-cance in evaluating prognosis of HER-2 negative breast cancer.
出处 《现代肿瘤医学》 CAS 2014年第10期2322-2325,共4页 Journal of Modern Oncology
基金 国家自然基金青年基金资助项目(编号:81101816) 江苏省中医药管理局开放性课题资助项目(编号:JD11025)
关键词 乳腺癌 HER-2阴性 血管内皮生长因子 环氧化酶-2 breast cancer HER - 2 negative vascular endothelial growth factor cyclooxygenase - 2
  • 相关文献

参考文献15

  • 1Badve S, Dabbs DJ, Schnitt S,et al. Basal - like and triple - nega-tive breast cancers : A critical review with an emphasis on the impli-cations for pathologists and oncologists[ J]. Mod Pathol,2011,24(2):157 -167.
  • 2Maciejczyk A. New prognostic factors in breast cancer[ J]. Adv ClinExp Med,2013,22(l) :5 -15.
  • 3Tagliabue E,Campiglio M, Pupa SM,et al. The HER - 2 world:Better treatment selection for better outcome [ J ]. J Natl Cancer InstMonogr,2011,43:82 -85.
  • 4Maae E,Nielsen M,Steffensen KD,et al. Estimation of immunohis-tochemical expression of VEGF in ductal carcinomas of the breast[J]. J Hisochem Cytochem,2011,59(8) :750 -760.
  • 5Ghasemi M, Emadian 0, Naghshvar F, et al. Immunohistochemicalexpression of vascular endothelial growth factor and its correlationwith tumor grade in breast ductal carcinoma[ J]. Acta Medica Iran-ica,2011,49(12) :776-779.
  • 6Von MG, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapyand bevacizumab for HER -2 negative breast cancer[ J] . N Engl JMed,2012,66:299 -309.
  • 7Miles DW, Haas SL, Dirix LY,et al. Biomarker results from theAVADO phase 3 trial of first - line bevacizumab plus docetaxel forHER -2 negative metastatic breast cancer[ J]. Br J Cancer,2013,108:1052-1060.
  • 8Marty M, Pivot X. The potential of anti - vascular endothelialgrowth factor therapy in metastatic breast cancer: Clinical experi-ence with anti - angiogenic agents focusing on bevacizumab [ J].Eur Cancer,2008,44(7) :912 -920.
  • 9Lucarelli AP,Martins MM,Montor W,et al. Cyclooxygenase -2 andhuman epidermal growth factor receptor type 2 ( HER -2) expres-sion simultaneously in invasive and in situ breast ductal carcinoma[J].Sao Paulo Med J,2011,129(6) :371 -379.
  • 10Thorat D,Sahu A,Behera R,et al. Association of osteopontin andcyclooxygenase - 2 expression with breast cancer subtypes andtheir use as potential bioraarkers[J]. Oncol Lett,2013,6: 1559 -1564.

二级参考文献25

  • 1李玉明,詹文华,韩方海,何裕隆,彭俊生,董文广,汪建平,蔡世荣,马晋平,赵刚.大肠癌同时性肝转移外科治疗的预后因素分析[J].中华普通外科杂志,2005,20(10):625-628. 被引量:16
  • 2Ildiko Csiki,Kiyoshi Yanagisawa.Thioredoxin-1 modulates transcriptien of cyclooxyg-chase-2 via hypoxia-inducible factor -1 α in non-small cell lung cancer[J].Cancer Res,2006,66:143-150.
  • 3Gallo O,Masini E,Bianchi B,et al.Prognostic significance of cy-clooxygenase -2 pathway and angiogenesis in head and neck squamous cell carcinoma[J].Hum Pathol,2002,33(7):708-714.
  • 4Yan Z,Subbaramainh K,Camilli T,et al.Hpyrene induces the transcription of cycloygenase-2 in vascular signal regulated kinase and NF-Kappaβ[J].J Biol Chew,2000,275 (7):497-499.
  • 5Berggren M,Gallegos A,Gasdaska JR,et al.Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines and the effects of serum stimulation and hypoxia[J].Anticancer Rse,2006,16:3459-3466.
  • 6Gasdaska PY,Oblong JE.Thiredoxin is identical to that of the autocrine growth factor human adult T cell derived factor(ADF):Thioredoxin mRNA is elevated in some human tumors[J].Biochim Biophys Acta,2005,1218:292-296.
  • 7Joanne R,Brown,Raymond N.COX-2:A molecular target for colorectal cancer prevention[J].J Clin Oncol,2005,23:2840-2854.
  • 8Ramanathan PK,Kirkpatrick DL,Belanicp,et al.A Phase 1 pharmacokinetic and pharmac-odynamic study of PX-12,a novel inhibitor of thioredoxin-1,in patients with advanced solid[J].Clin Cancer Res,2007,13(7):2109-2014.
  • 9Seungjin Kim,Yasuo Miyoshi.High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer[J].Biochem Biophys Res Commun,2007,36(2):362-366.
  • 10Chen XP,Lins,Tang WX,et al.Nuclear thioredoxin-1 is required to suppress cisplatin-mediated apoptosis of MCF-7 cells[J].Clin Cancer Res,2007,13(7):2109-2014.

共引文献32

同被引文献40

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部